1Wiechmann L,Sampson M,Stempel M.Presenting Features of Breast Cancer Differ by Molecular Subtype[J].Ann Surg Oncol,2009,16:2705-2710.
2Carol A,Parise,Katrina R,et al.Breast Cancer Subtypes as De?ned by the Estrogen Receptor(ER),Progesterone Receptor(PR),and the Human Epidermal Growth Factor Receptor 2 (HER-2) among Women with Invasive Breast Cancer in California,1999 -2004[J].The Breast J,2009,15:593-602.
3Hugh J,Hanson J,Cheang MC,et al.Breast cancer subtypes and response to docetaxel in node-positive breast cancer:use of an immunohistochemical definition in the BCIRG 001 trial[J].J Clin Onco1,2009,27:1168-1176.
8Slamon D,Leyland-Jones B,Shak S,et al.Addition of Herceptin(humanized anti -HER-2 antibody) to first line chemotherapy for HER-2overexpressing metastatic breast cancer(HER-2 +/MBC) markedly increases anticancer activity:a randomize,multinational controlled phase Ⅲ trial[J].Proc Am Soc Clin Oncol,1998,17:98a.
9Norton L,Slamon D,Leyland-Jones B.Overall survival advantage to simultaneous chemotherapy plus the humanized anti-HER-2monoclonal antibody Herceptin in HER-2 overexpressing metastatic breast cancer[J].Proc Am Soc Clin Oncol,1999,18:127a.
10Forbes JF,Pienkowski T,Valero V,et al.BCIRG 007:Randomized phase Ⅲ trial of trastuzumab plus docetaxel with or without carboplatin first line in HER-2 positive metastatic breast cancer (MBC)[J].Proc Am Soc Clin Oncol,2006 24:LBA516.
5Piccart-Gebhart M J, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med,2005, 353 (16) :1659-1672.
6Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med,2006,354(20) :2103-2111.
7Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 2001,344 ( 1 Suppl 3 ) :783-792.
8Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase Ⅱ study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol, 2005,23 ( 10 ) :2162-2171.
9Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol, 2003, 21 ( 21 ) : 3965-3971.
10Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol, 2002,20 (3) :719-726.
8Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J]. New Engl J Med, 2005, 353(16):673-684.
9孙燕;石远凯.临床肿瘤内科手册[M]北京:人民卫生出版社,2009440.
10Morgan GJ,Gregory WM. The role of maintenance thalidomide therapy in multiple myeloma:MRC Myeloma Ⅸ results and meta-analysis[J].{H}Blood,2012,(01):7-15.
